Deferoxamine (Desferal)-induced ocular toxicity.
A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy. Treatment with two courses of high-dose deferoxamine, an iron chelator (130-180 mg/kg/day), along with low-dose ARA-c (5 mg/kg/day) caused a remarkable decrease of the WBC and fetal Hb. Three days following the last dose of deferoxamine, the patient experienced an acute visual loss, confirmed by electroretinogram (ERG) and visual evoked response (VER). Slight improvement occurred a few days later, but the patient developed severe pancytopenia and died of Klebsiella septic shock. The ocular manifestations were attributed to deferoxamine toxicity in light of the rapid onset after first exposure, the electrophysiological pattern of metabolic damage in the ERG and VER, and the long interval between the last chemotherapy and BMT. The pathogenesis of deferoxamine toxicity is discussed.
Kaplinsky
C
C
Department of Pediatric Hematology-Oncology, Beilinson Medical Center, Petah Tikva, Israel.
Stark
B
B
Goshen
Y
Y
Yaniv
I
I
Bashara
S
S
Zaizov
R
R
D001766:Blindness / Q000139:chemically induced* / Q000209:etiology; D002675:Child, Preschool; D003676:Deferoxamine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D009901:Optic Nerve Diseases / Q000139:chemically induced* / Q000150:complications
D003676:Deferoxamine